Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11868MR)

This product GTTS-WQ11868MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11868MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3081MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ9848MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ4299MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ3469MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BA1126
GTTS-WQ1142MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ13346MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-06801591
GTTS-WQ14486MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ10271MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LFG 316
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW